Maya Clark Cutaia, PhD, RN, is the inaugural Evelyn Lauder Associate Dean for Nurse Practitioner Programs and Professor at the Hunter-Bellevue School of Nursing at Hunter College.

Neighborhood Disadvantage As a Clinical Variable For Kidney Care, With Maya Clark Cutaia, PhD, RN

Considering neighborhood disadvantage as a clinical variable may be a useful strategy for supporting populations with reduced socioeconomic status in their kidney health, especially 

Lifelong exposure to adverse conditions within disadvantaged neighborhoods has been associated with an increased risk for kidney disease, along with accelerated progression. Despite this population’s adverse clinical outcomes, including progression to end-stage kidney disease, many needs remain unmet.

“In kidney disease, it looks like individuals who have higher exposure to environmental stressors,” said Maya Clark Cutaia, PhD, RN, the inaugural Evelyn Lauder Associate Dean for Nurse Practitioner Programs and Professor at the Hunter-Bellevue School of Nursing at Hunter College, in an interview with 

 “That may be things like pollution and heat, which we're seeing a lot nowadays, when, you know, focusing on climate work, fewer safe spaces so there's an inability to exercise, there's less reliability for access to healthy food and transportation, and then there's just a litany of other barriers that make it difficult for patients to get to primary care or nephrology care, and so it increases their risk, and therefore can accelerate their progression.”

Patients with kidney failure living in disadvantaged neighborhoods face barriers to care. Recent research has reported an association with neighborhood disadvantage and access to waitlisting and kidney transplantation. Furthermore, other evidence stated for > 1 in 10 of the most disadvantaged communities (11.7%) lacked a dialysis facility within a 30-minute drive compared with roughly 1 in 40 of the least disadvantaged communities (2.3%).

Even before patients reach ESKD, there may be missed opportunities for identifying CKD in its earlier stages and to intervene sooner, an aspect especially heightened in this patient population because of the aforementioned barriers to care.

“When we think about neighborhood disadvantage, it does mean there are differences in screening and CKD development or acknowledgement, diagnosis and management, suggesting that there are missed opportunities happening way downstream. It's a difficult conundrum because we're often seeing them being diagnosed at a point when complications already exist, and so our window for intervention is smaller.”

Surachman A. Neighborhood Deprivation, Financial Hardship, and Decrements in Kidney Function Across a Decade. 

https://doi.org/10.1093/geroni/igaf122.4413

Li Y, Menon G, Kim B, et al. Residential Neighborhood Disadvantage and Access to Kidney Transplantation. 

https://doi.org/10.1001/jamanetworkopen.2025.49679

Eisenbeisz ME, Chertow GM. Diminished Access to Dialysis in Disadvantaged Communities—Driving Toward More Equitable Care. 

. Published online February 23, 2026. doi:

https://doi.org/10.1001/jamainternmed.2025.8037

Videos

Should clinicians consider neighborhood disadvantage the same way they measure proteinuria and GFR for kidney health?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

On March 16, Eli Lilly and Company released 

 from the phase 3 ADorable-1 study regarding lebrikizumab (Ebglyss) and its success in treating those with moderate to severe atopic dermatitis, including infants and children as young as 6 months.

These data suggest both of the ADorable-1 study’s co-primary endpoints were met while using this interleukin (IL)-13–targeting monoclonal antibody, currently 

-approved for moderate to severe atopic dermatitis in adults and adolescents.

 Lilly has also indicated its intention to submit the data to US and international regulators for a label expansion in younger pediatric patients.

Amy Paller, MD, chair of the department of dermatology at Northwestern University and an investigator in the study, spoke with 

 following the release of these findings. The following is a Q&A discussion with Paller about the biggest highlights:

What would you say stood out most among these findings from ADorable-1 as an investigator on this trial?

 The biggest takeaway is that we've been living with one advanced systemic only, for such a long time now, yet we have such a large part of our population, the pediatric population under 12, who have moderate to severe atopic dermatitis. They are just not responding well enough to topicals, or parents are putting on so much steroid that I'm sure that it's having some adverse effects over time. Not to mention the burden of disease and spending so much time.

The fact that we now have a second one that, hopefully, will move forward for FDA clearance is really thrilling to us as pediatric dermatologists. We've been waiting for this for a long time. We don't have any options other than what we've had for decades: methotrexate and cyclosporine. These are the options for kids who don't respond well to dupilumab or have an issue with it.

ADorable-1 enrolled patients as young as 6 months, a population where we have very few approved targeted options. How meaningful are these topline results to you as an investigator, and what does a 63% EASI-75 response rate tell us about the potential role of selective IL-13 inhibition in this age group?

 What it tells us is probably going to be on par with the type of changes that we've seen with dupilumab, and that's great. You know, we've all now had some experience with those who are 12 and above. We know that they're very different, these approaches, and we can't take a response to one and just apply it to the other. They're quite different, and again, it gives us an option. But it tells us that it's an option that looks to be pretty promising, and the majority, that is two-thirds of children within as short a period of 16 weeks, will have a tremendously meaningful improvement in their disease.

The trial used weight-based dosing alongside background topical corticosteroids. Can you walk us through the rationale for that design, and how confident are you that the efficacy signal here reflects lebrikizumab's contribution specifically, rather than the combination with topical therapy?

This has also been done with these other pediatric trials, including with dupilumab. It's just really not considered ethical in children to not provide some modicum of relief. Of course, these are children in whom the topicals weren't enough anyway, so putting them on a topical steroid on both arms is really an ethical move to try to assuage some of the pain, itch, and terrible aspects of this disease. That's where that comes from. The weight-based dosing, of course, reflects the fact that this is pediatrics.

We can't just give them adult doses, but it is tiered. So, the smallest children in the study would be getting something like the two loading doses, and then going to 125 every 4 weeks. Whereas the older children in the study would be, depending on where they were, if they were 40 kilograms and above, on the standard 250 milligram for 0, 2 weeks, and then every 2 weeks after that. If they were in the next tiered group, that is under 40, but I think it was over 15 milligrams, they would be getting the 250 after that, 2 weeks on an every-4-week basis.

Atopic dermatitis in infants and toddlers carries a significant burden not just for the patient but for the whole family. Beyond the clinical endpoints, what did you observe in terms of the real-world impact on patients and caregivers throughout the trial?

I don't know that that data is out there in the public domain yet, but I will just say, from my own experience, when you get something that works great, you get a lot of smiles on everybody's face. This is a disease that has a terrible burden, not just for the young children, but for the entire family. The parents don't sleep. When the kids don't sleep, the parents spend more time at the doctors and out of work. Kids are homesick, and it's a tremendous burden for, not just the parents but, of course, the entire family. Being able, in a relatively short period of time in this study, to turn around the burden of this disease really helps the physical and emotional burden for the entire family.

With Lilly planning regulatory submissions based on these data, what would a label expansion down to 6 months mean for how pediatric dermatologists approach treatment sequencing?

As I mentioned, it gives us options. I think we're very used to using dupilumab. I don't think that's going to go away, but I think that we now have an option for one or the other. There is going to potentially be a difference. We'll see what the FDA does. I really don't know, but the cutoff for going every 2-week-dosing with dupilumab was set at 30 milligrams. You get that 200-milligram every 2 weeks. Here, it's set at 40. So that means under 40, they'd be every 4 weeks based on the FDA. I don't know if that'll make a difference, but it gives a certain group of kids more of an on-label every 4 weeks.

For dupilumab, I often use it every 4 weeks for the kids in that group. That's 30 and above. This is just because that's the on-label for Europe, and it works just fine. The answer to your question is that we have options now for these kids of this age. We can have first-line dupilumab, we can have first line lebrikizumab. We certainly have options if they don't do well with whatever our first choice is.

What remaining questions would you most like answered in the next phase of research for lebrikizumab in this younger patient population?

I think it's always important to see a larger group beyond what's in the study. We want to see what the real-world experience is with first-line lebrikizumab, with changing from dupilumab to lebrikizumab. We certainly didn't see much in terms of any kind of adverse events during this trial, no new signals, and nothing of concern. But we'll keep an eye on whether there seems to be any difference with instance of ocular surface disease, although it's so low with dupilumab as well in this young population.

I think we're also going to be looking at the long term. One of the big questions: We talk now about the potential that dupilumab, which we know is on-label for asthma, and we know it is helpful for a variety of allergic and new mediated disorders. [The question is] whether there is going to be a role in reducing the development of other atopic diseases, in addition to reducing the severity of those diseases while on the drug; we just don't know how much of that is.

Specifically, the fact that the IL-4 receptor inhibitor of dopamine also inhibits IL-4 signaling directly…We may not get that with the IL-13-specific targeting. I think that will be an interesting question to look at further, looking at the development or the occurrence of these other allergic disorders with IL-13. That's going to be something. Then obviously, other questions that we have as well, are why vaccines? Is there any concern with giving a live vaccine? Theoretically, there would not be, but obviously that remains to be answered with real data. I think those are the 2 big questions that are out there.

The quotes used in this interview were edited for the purposes of clarity.

Disclosures for Paller include the following: AbbVie, AnaptysBio, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi – investigator; AbbVie, Amgen, Asana, Dermavant, Dermira, Eli Lilly, Forte, Galderma, LEO Pharma, Matrisys Bioscience, Menlo Therapeutics, MorphoSys/Galapagos, Novartis, Pfizer, Regeneron Pharmaceuticals. Inc., Sanofi – consultant.

Campbell P. Phase 3 Trial Supports Lebrikizumab in Pediatric Atopic Dermatitis. HCPLive. March 16, 2026. Accessed March 17, 2026. 

https://www.hcplive.com/view/phase-3-trial-supports-lebrikizumab-in-pediatric-atopic-dermatitis

Eli Lilly and Company. Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis | Eli Lilly and Company. Eli Lilly and Company. Published March 16, 2026. Accessed March 17, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-ebglyss-lebrikizumab-lbkz-first-and-only-selective-il-13

Articles

Phase 3 ADorable-1 topline data support lebrikizumab, a selective IL‑13 monoclonal antibody, in moderate-to-severe atopic dermatitis for patients aged 6 months to 18 years, meeting both co-primary endpoints and achieving ~63% EASI‑75 at 16 weeks with background topical corticosteroids. Weight-tiered dosing aligned with pediatric pharmacology and mirrored ethical trial norms for symptom control. A potential label expansion would add a second advanced systemic option for younger children, enabling alternative first-line sequencing and switch strategies beyond dupilumab and legacy immunosuppressants.

Following the release of new results from the phase 3 ADorable-1 trial on lebrikizumab in pediatric patients, Amy Paller, MD, speaks in a new Q&A interview.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Significance of ADorable-1 Data on Lebrikizumab in Children with Atopic Dermatitis, With Amy Paller, MD

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

AHA/ACC Dyslipidemia Guidelines Reinstate LDL-C Goals, With Viet Le, DMSc, PA-C

On March 13, 2026, the American College of Cardiology (ACC) and American Heart Association (AHA) released an updated clinical guideline for the management of 

, replacing the 2018 Guideline on the Management of Blood Cholesterol.

Among the most major changes in these guidelines is the shift from percent reduction of LDL-C back to specific, targeted goals. The 2018 version encouraged the use of percent LDL-C reductions as a method of monitoring lipid levels and guiding lipid-lowering therapy (LLT) across the board. Additionally, secondary prevention now includes LDL-C goals as well, with recommendations shifting for LDL-C ≥190 mg/dL and familial hypercholesterolemia (FH).

“I love coming back to goals,” Viet Le, DMSc, PA-C, associate professor of research and preventive cardiology PA at Intermountain Health and ACC editor in chief, told 

 in an exclusive interview. “It was a little nebulous to just throw out percent reduction of LDL cholesterol, so I think it’s helpful for patients and for clinicians alike to be able to see goals of where we’re going.”

Percent LDL-C reductions were widely considered vague, given their subjectivity between patients. Now, although the guidelines retain percentage reduction in LDL-C as a priority for individuals, with goals for percent reduction dependent on the level of 

atherosclerotic cardiovascular disease (ASCVD

) risk, LDL-C and non-HDL-C treatment goals are once again forming the backbone of LLT guidance.

Specific goals are largely determined by PREVENT risk tier. Those at borderline risk – between 3 and <5% - have a goal LDL-C of <100 mg/dL and a goal non-HDL-C of <130 mg/dL. Patients at intermediate risk, or from 5 to <10%, have a goal LDL-C of <100 mg/dL. Those at high risk - ≥10% - have a goal LDL-C of <70 mg/dL and non-HDL-C of <100 mg/dL and should be given ezetimibe if the goal is not met on a maximum statin.

Secondary prevention markers will also incorporate LDL-C goals – patients at very high risk, or with ≥2 major ASCVD events or 1 event and ≥2 high-risk features have a goal LDL-C of <55 mg/dL and non-HDL-C <85 mg/dL and should have ezetimibe added to max statin. Patients not at very high risk, however, have an LDL-C goal of <70 mg/dL and non-HDL-C of <100 mg/dL. Additionally, based on data from CLEAR OUTCOMES, bempedoic acid and inclisiran are now formally positioned as add-on options for very high-risk patients who cannot reach goal.

Finally, patients with severe hypercholesterolemia or FH have received recommendations as well. Patients with ASCVD have an LDL-C goal <55 mg/dL and should receive ezetimibe, while those without ASCVD but with heterozygous HF (HeFH) have a goal LDL-C <70 mg/dL with ezetimibe, PCSK9 inhibitors, and/or bempedoic acid added to max statin. Additionally, standard risk calculators like PREVENT and PCE explicitly not recommended for HeFH – the authors cite their tendency to underestimate risk. Instead, panel-based genetic testing should be used for FH.

“This is important,” Le said. “These are individuals with 1 event and 2 or more major risk factors, or 2 or more major events. They’re very high risk. And the guidelines make this clear. Most of our patients end up in the very high risk category if they have any events. Typically, they have 2 or more risk factors with them. So, less than 55 mg/dL should really be the clarion call and the goal that we think about for most of these individuals.”

Editors’ Note: Le reports disclosures with Janssen, Pfizer, Novartis, Idorsia, Amarin, and Lexicon.

Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online March 13, 2026. 

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25). 

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the return of LDL-C target goals for ASCVD prevention.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Strategic Alliance Partnership

Désirée Larenas-Linnemann, MD, from Hospital Médica Sur

Barriers to Using SLIT, With Désirée Larenas-Linnemann, MD

2026 American Academy of Allergy, Asthma & Immunology

, from Hospital Médica Sur, shared persistent real‑world barriers to broader adoption of 

 in the United States. Although SLIT can offer a home‑based alternative to injections, financial and practical hurdles continue to limit its uptake.

“It’s only one allergen that you can give in a tablet,” Larenas-Linnemann said. “If you want to do 2 allergens, you have to give 2 tablets, which doubles the cost. Most tablets are not covered by insurance.”

She further emphasized the complexity of prescribing tablets for allergic asthma, as not all formulations have FDA approval for this indication. However, since many patients also have concomitant allergic rhinitis, clinicians often navigate this off-label use.

Adherence is another critical factor. Larenas-Linnemann described wide variability among patients, observing that while some strictly follow daily dosing, others stretch vials beyond recommended intervals, undermining therapeutic effectiveness.

“If you really want to have good effects, you need to have your monthly dose,” she said. “You need to have your daily dose, ideally, with the tablets.”

Emerging research on multi-allergen SLIT, particularly in liquid form, may expand treatment options, though evidence remains limited. Larenas-Linnemann said it could be possible to use 2 tablets for multi-allergen therapy, but evidence is scarce. European guidelines suggest a 30-minute interval, but this is based on a single study, and the effect of administering 2 tablets simultaneously remains unknown.

“It's a recommendation without solid evidence behind it,” Larenas-Linnemann said.

When it comes to multi‑allergen SLIT, Larenas‑Linnemann emphasized careful patient selection. Typical combinations might include grass pollen, tree pollen, cat dander, and house dust mite. Clinicians must ensure the patient is clinically reactive to these allergens, as positive skin tests alone do not always reflect current symptomatic allergy. For example, patients may test positive for mold exposure they encountered years ago but no longer experience symptoms in their current environment, making immunotherapy unnecessary for that allergen.

Evidence for multi‑allergen liquid SLIT remains limited but promising. Studies combining 2 allergens, such as house dust mite and grass pollen, have demonstrated efficacy over 1 to 2 years. Trials mixing 3 or 4 allergens show weaker but still observable responses, and even studies attempting 10-allergen combinations suggest a signal of benefit when focusing on relevant allergens. Larenas‑Linnemann noted that statistical significance may be limited by small sample sizes.

In her practice, she limits multi‑allergen therapy to no more than four allergens, using liquid formulations with high concentrations

to maximize the potential therapeutic effect. The goal is to deliver the strongest possible dose for each relevant allergen, balancing efficacy with safety.

Larenas-Linnemann has no relevant disclosures.

Larenas-Linnemann, D. What Should You Know About SLIT in 2026? Session presented at the American Academy of Allergy, Asthma, & Immunology (AAAAI) in Philadelphia on February 28, 2026.

High costs, limited insurance coverage, and adherence challenges remain key barriers to broader SLIT use in the US, Larenas-Linnemann says in an interview at AAAAI 2026.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Kidney Disease: Improving Global Outcomes (KDIGO)

2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD)

, one of the most widely used global resources for CKD evaluation and management.

The update will focus on Chapter 3, “Delaying CKD progression and managing its complications,” with particular emphasis on medical management using newer therapies in light of the evolving therapeutic landscape.

At the time the 2024 guideline was published, recommendations for therapies such as ACE inhibitors, ARBs, SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs were based on the best available evidence, primarily in patients with diabetes or significant albuminuria, where most trial data were available. The guidance used a cautious, stepwise approach to balance potential benefits with safety considerations, including hyperkalemia and changes in kidney function. 

Since then, emerging trial data have demonstrated broader kidney and cardiovascular benefits of these therapies, including in people without diabetes, prompting KDIGO to initiate a focused update to ensure recommendations reflect the most current evidence.

“Since the publication of the 2024 KDIGO CKD Guideline, new data continue to emerge that have important implications for how we slow CKD progression and manage complications,” said Adeera Levin, MD, co-chair of the 2024 guidelines. “This focused update will ensure that KDIGO recommendations reflect the latest evidence and continue to support healthcare professionals caring for people living with CKD.”

These data include several therapies, which have been changing CKD management, including sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 (GLP-1)-based therapies, and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) in people with CKD without diabetes.

The update will follow the rigorous KDIGO guideline development methodology, including systematic evidence review and multidisciplinary expert input. Updated systematic evidence reviews will inform the decision to update existing recommendations and practice points. Levin is on board for the new update process, along with the original co-chair, Paul Stevens, MB, and a majority of the 2024 CKD Guideline Work Group, in order to ensure continuity and expertise.

“New cardiovascular and kidney outcomes trial data for SGLT2 inhibitors, GLP-1-based therapies, and nonsteroidal MRAs are raising important questions about how these therapies should be used in people with CKD who do not have diabetes,” said Stevens. “Our goal is to carefully review this evolving evidence and provide clear, practical guidance for healthcare professionals around the world.”

Kidney Disease: Defining Global Outcomes (KDIGO). CKD Evaluation and Management – KDIGO. KDIGO. Published 2024. Accessed March 17, 2026. 

https://kdigo.org/guidelines/ckd-evaluation-and-management/

Babitt JL, Berns JS, Bozkurt B, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). 

https://doi.org/10.1016/j.kint.2025.06.005

KDIGO has initiated a focused update to the 2024 CKD Clinical Practice Guideline, targeting Chapter 3 on delaying progression and managing complications. The update is driven by emerging cardiovascular and kidney outcomes data extending benefits of cornerstone pharmacotherapies beyond the original evidence base centered on diabetes and/or significant albuminuria. KDIGO aims to recalibrate prior stepwise recommendations for ACEi/ARB, SGLT2 inhibitors, GLP-1–based therapies, and nonsteroidal MRAs, balancing efficacy with safety concerns such as hyperkalemia and acute eGFR changes through a rigorous evidence-review process.

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies


Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity. 

Expanding Use of Lower-Quality Kidneys Could Boost Transplants, Improve Equity, With Matthew Kaufmann, PhD

Natasha Mesinkovska, MD, PhD, is a dermatologist and researcher at the University of California, Irvine School of Medicine Department of Dermatology.

This segment of the latest episode of The Medical Sisterhood highlights insights into the career of Natasha Mesinkovska, MD, PhD.

Resilience, Rejection, and Recognition in Academic Dermatology

Nicole Ramsey, MD, PhD, assistant professor of pediatrics in the division of pediatric allergy and immunology at the Icahn School of Medicine at Mount Sinai.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Lung Cancer

Race-Neutral Spirometry Gains Support as Standard Practice, With Nicole Ramsey, MD, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA has issued its third CRL to topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease.

FDA News

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Martinez and Harper outline practical workflows for initiating and titrating cardiac myosin inhibitors, emphasizing multidisciplinary team structure, telemedicine, and logistics around REMS and imaging.

Video Series

Implementing Cardiac Myosin Inhibitors in oHCM: Workflow and Team-Based Care

Martinez and Harper describe a hub-and-spoke model for HCM care, follow-up cadence, and a structured “4-pillar” framework for longitudinal management, including imaging, biomarkers, and family-based risk strategies.



Comprehensive oHCM Follow-up: Hub-and-Spoke Care and 4-Pillar Framework

Martinez and Harper review real-world REMS data on cardiac myosin inhibitors, refine approaches to safety monitoring, and question how frequently echocardiography is truly needed in stable oHCM patients.

Long-term Safety, REMS Data, and Echo Monitoring for oHCM Therapies

Corey Cavanaugh, DO, is an academic nephrologist at the Cleveland Clinic. 

Even Routine Urinalysis Can Reveal Hidden IgA Nephropathy, Especially in Young Adults

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Even Routine Urinalysis Can Reveal Hidden IgAN In Young Patients, With Corey Cavanaugh, DO

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting PREVENT and a renewed focus on Lp(a).

ACC/AHA Dyslipidemia Guidelines Focus on PREVENT, Lp(a), With Viet Le, DMSc, PA-C

Emily McDonald, MD, MSc, is an associate professor of medicine at McGill University.

McDonald discusses new trial data suggesting an initial vancomycin taper may reduce early recurrence of C difficile infection.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

C Difficile Infection

C. difficile condition center page, resources on the topics of medical news and expert insight into Clostridium difficile can be found. Content includes articles, interviews, videos, podcasts, and breaking news on C. diff research, treatment, and drug development.

Latest News

Neighborhood Disadvantage As a Clinical Variable For Kidney Care, With Maya Clark Cutaia, PhD, RN

Significance of ADorable-1 Data on Lebrikizumab in Children with Atopic Dermatitis, With Amy Paller, MD

AHA/ACC Dyslipidemia Guidelines Reinstate LDL-C Goals, With Viet Le, DMSc, PA-C

Barriers to Using SLIT, With Désirée Larenas-Linnemann, MD

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies